top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago


enGene's Non-Viral Gene Therapy for Bladder Cancer Heads to the FDA
enGene's non-viral gene therapy detalimogene cleared detectable cancer in 56% of evaluated patients with BCG-unresponsive bladder cancer, and 86% kept their bladders. The company plans to start its FDA application by the end of 2026.
6 days ago


FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
Oct 29


Should Gene Therapy Be Used for Common Diseases? Two Cardiologists Propose Five Questions
One-time genetic treatments are moving from rare diseases to common ones like high cholesterol. In JAMA Internal Medicine, two University of Michigan cardiologists explain why permanence, rare side effects and cost call for a new framework.
Oct 22


One CRISPR Dose, 87% Fewer Attacks: Inside Intellia's Phase 3 Win for Hereditary Angioedema
Intellia's one-time CRISPR therapy lonvo-z cut hereditary angioedema attacks by 87% in the Phase 3 HAELO trial. In its August update, the company set a U.S. launch target of early 2027. Here's how it works.
Aug 5


FDA Draft Guidance Lets Gene-Editing Developers Build on What's Already Known
A June 2026 FDA draft guidance lets developers of genome-editing therapies reuse prior manufacturing, nonclinical and clinical knowledge. Here's why the platform approach could speed rare-disease cures.
Jun 2


One Infusion, Lower Cholesterol: Early Data Back Lilly's Bet on Verve
Phase 1 data for VERVE-102, a one-time base-editing treatment that switches off PCSK9, showed LDL cholesterol cuts of up to 62% lasting up to 18 months. Here's what it means for heart disease.
May 24


CRISPR Gene-Editing Therapies Make Strides, but Cost and Accessibility Remain Key Challenges
As CRISPR-based therapies edge closer to becoming mainstream, groundbreaking treatments for blood disorders and cancer are making their mark. One of the most exciting developments is Casgevy, a gene-editing therapy that has shown remarkable success in treating sickle-cell disease and β-thalassaemia. Approved in both the UK and US, Casgevy works by reactivating fetal hemoglobin, offering patients a chance at long-term relief with fewer blood transfusions and hospital visits. W
Dec 19, 2024


New Gene-Editing Technique: A Better Alternative to CRISPR for Fixing Cystic Fibrosis Mutation
A team from the Broad Institute of MIT and Harvard, along with Harvard University and the Howard Hughes Medical Institute, has made exciting strides in using a gene-editing tool called prime editing to tackle the mutation responsible for cystic fibrosis in human lung cells. This innovative approach offers a more precise and safer alternative to traditional CRISPR methods, significantly lowering the chances of unintended changes to the genome. Cystic fibrosis is a genetic diso
Sep 10, 2024


Two New CRISPR-Based Gene Therapies for Sickle Cell Anemia Approved by the FDA
The FDA recently approved two groundbreaking CRISPR-based gene therapies for curing Sickle Cell Disease (SCD): Casgevy - developed by Vertex Pharmaceuticals and CRISPR Therapeutics Lyfgenia - developed by Bluebird Bio By targeting the BCL11A gene, these therapies successfully correct SCD mutations and increase fetal hemoglobin (HbF) levels in patients. This is exciting news for patients and families living with this painful disease, as it presents a potential cure rather than
Mar 25, 2024
bottom of page


